Plus Therapeutics updates 2025 executive pay details

Plus Therapeutics updated its executive pay disclosure by adding 2025 discretionary cash bonuses for its named executive officers.

Rhea-AI Filing Summary

Plus Therapeutics updated its executive pay disclosure by adding 2025 discretionary cash bonuses for its named executive officers. The Compensation Committee approved these bonuses on February 9, 2026, completing the previously incomplete 2025–2024 summary compensation table originally referenced in a Form S-1 registration statement.

For 2025, President and CEO Marc H. Hedrick, M.D. received total compensation of $5,566,732, including a $585,000 salary, option awards valued at $3,531,841, restricted stock awards of $1,100,647, non-equity incentive plan compensation of $305,663, and other compensation of $43,581. Chief Financial Officer Andrew Sims received 2025 total compensation of $1,631,279, including a $390,000 salary, option awards of $810,388, restricted stock awards of $264,154, non-equity incentive plan compensation of $149,175, and other compensation of $17,562. Former Chief Medical Officer Norman LaFrance, M.D., who stepped down on June 11, 2024, shows no 2025 compensation, with 2024 total compensation of $285,912.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Plus Therapeutics (PSTV) disclose in this 8-K filing?

Plus Therapeutics updated its 2025 and 2024 executive compensation table. The company disclosed final discretionary cash bonuses and total pay figures for its named executive officers, completing information initially referenced in a prior Form S-1 registration statement with the SEC.

How much total compensation did PSTV’s CEO receive for 2025?

President and CEO Marc H. Hedrick, M.D. received 2025 total compensation of $5,566,732. This includes a $585,000 salary, $3,531,841 in option awards, $1,100,647 in restricted stock awards, $305,663 in non-equity incentive pay, and $43,581 in other compensation.

What was Plus Therapeutics CFO Andrew Sims paid in 2025?

Chief Financial Officer Andrew Sims received 2025 total compensation of $1,631,279. His package included a $390,000 salary, $810,388 in option awards, $264,154 in restricted stock, $149,175 in non-equity incentive compensation, and $17,562 categorized as all other compensation and benefits.

How does the filing describe share-based awards for PSTV executives?

The filing states that option and restricted stock award values reflect aggregate grant date fair value. These amounts are calculated under ASC Topic 718 and, following SEC rules, exclude estimated forfeitures related to service-based vesting conditions for the named executive officers.

What benefits are included in ‘All Other Compensation’ for PSTV executives?

All Other Compensation includes standard employee benefits for executives. The filing specifies items such as 401(k) matching contributions and health and life insurance premiums, which are added to salary, equity awards, and bonuses to determine each executive’s total compensation for the year.

Why does former Chief Medical Officer Norman LaFrance show no 2025 compensation?

The table shows no 2025 amounts for former Chief Medical Officer Norman LaFrance because he stepped down on June 11, 2024. For 2024, his compensation totaled $285,912, including salary and other compensation, but no option or restricted stock awards are reported for that year.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:09 PM Learn about SEC filing dates

0001095981false00010959812026-02-092026-02-09

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 9, 2026

PLUS THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-34375	33-0827593
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
6420 LEVIT GREEN BOULEVARD Suite 310
Houston, Texas				77021
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (737) 255-7194

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		PSTV		The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 9, 2026, Plus Therapeutics, Inc. (the “Company”) filed a Registration Statement on Form S-1 (File No. 333-292637) with the Securities and Exchange Commission (as amended, the “Registration Statement”). Pursuant to Instruction 1 to Item 402(c)(2)(iii) and (iv) of Regulation S-K, the “Summary Compensation Table for 2025 and 2024” included in the Registration Statement noted that the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) had not yet determined the amount of discretionary cash bonuses payable to the Company’s principal executive officer and up to two of the most highly compensated executive officers other than the principal executive officer (the “Named Executive Officers”) for the fiscal year ended December 31, 2025 (“Fiscal Year 2025”), and that the amounts of such discretionary cash bonuses would be disclosed in a Current Report on Form 8-K under Item 5.02(f) once the amounts are determined.

On February 9, 2026, the Compensation Committee approved discretionary cash bonuses payable to the Named Executive Officers for Fiscal Year 2025. In accordance with Item 5.02(f) of Form 8-K, set forth below is an updated “Summary Compensation Table for 2025 and 2024”, which includes the amount of discretionary cash bonuses payable to the Named Executive Officers for Fiscal Year 2025, as well as the total compensation figures for the Company’s Named Executive Officers for Fiscal Year 2025.

NEO		Year				Salary ($)				Option Awards ($)(1)				Restricted Stock Awards ($)(1)				Non-Equity Incentive Plan Compensation ($)				All Other Compensation ($)(2)				Total ($)
Marc H. Hedrick, M.D. President and Chief Executive Officer			2025				585,000				3,531,841				1,100,647				305,663				43,581				5,566,732
			2024				556,400				335,348				—				321,321				47,216				1,260,285
Andrew Sims Chief Financial Officer			2025				390,000				810,388				264,154				149,175				17,562				1,631,279
			2024				372,750				74,758				—				156,555				17,053				621,116
Norman LaFrance, M.D.(3) Former Chief Medical Officer			2025				—				—				—				—				—				—
			2024				258,446				—				—				—				27,466				285,912

(1)The amounts in this column reflect the aggregate grant date fair value of share-based awards granted to our NEOs during the years indicated. In accordance with SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service-based vesting conditions computed in accordance with ASC Topic 718.

(2)This column includes standard benefits, including a 401K match, and health and life insurance premiums.

(3)On June 11, 2024, Dr. LaFrance stepped down from his position as the Company’s Chief Medical Officer.
 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			PLUS THERAPEUTICS, INC.
Date:	February 13, 2026	By:	/s/ Marc H. Hedrick, M.D.
			Marc H. Hedrick, M.D. President and Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 30.2 KB